SBCSBC Medical Group Holdings Incorporated
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−5% a year). The price bakes in little to no growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SBC's price assumes
SBC Medical Group Holdings Incorporated trades at 11.2× earnings against 19.5× for the median Consulting Services name, cheaper than its own group.
Trailing P/E · Consulting Services median 19.5 · cheaper than the typical name in its group
- Price / sales
- 1.81
Price / sales · as of 2026-Q2
- Free cash flow yield
- 11%
Free cash flow yield · Consulting Services median 8.3%
- Growth the price implies
- −5.4%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / bookas of 2026-Q2
- 1.20
- EV / EBITas of 2026-Q2
- 2.60
- EV / salesas of 2026-Q2
- 0.97
- Industrials median P/E434 names
- 26.2
- Consulting Services median P/E10 names
- 19.5
- Free cash flow, trailing twelve months
- $62M
- Market capitalisation102.8 million shares, counted Jul 31, 2026
- $542M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Consulting Services
The closest names by size in the same industry